• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by BiondVax Pharmaceuticals Ltd.

    1/2/24 9:24:06 AM ET
    $BVXV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BVXV alert in real time by email
    6-K 1 ea190966-6k_scinaiimmun.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

    Under the Securities Exchange Act of 1934

     

    For the Month of December 2023

     

    Commission File Number: 001-37353

     

    SCINAI IMMUNOTHERAPEUTICS LTD.

    (Translation of registrant’s name into English)

     

    Jerusalem BioPark, 2nd Floor

    Hadassah Ein Kerem Campus

    Jerusalem, Israel

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

     

    Form 20-F ☒       Form 40-F ☐

     

     

     

     

     

    On December 29, 2023, Scinai Immunotherapeutics Ltd. issued a press release entitled “Scinai Immunotherapeutics Announces Exercise of Outstanding Warrants for $1.69 Million in Gross Proceeds” A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

     

    Exhibit No.   Description
    99.1   Press Release dated December 29, 2023.

     

    This Report on Form 6-K is hereby incorporated by reference into the registrant’s Registration Statements on Form S-8 (File No. 333-271293 and File No. 333-239344) and Form F-3 (File No. 333-274078), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

     

    1

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

      Scinai Immunotherapeutics Ltd.
         
    Date: January 2, 2024 By: /s/ Amir Reichman
        Amir Reichman
        Chief Executive Officer

     

     

    2

     

     

     

    Get the next $BVXV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BVXV

    DatePrice TargetRatingAnalyst
    1/26/2022$7.00Buy
    Aegis Capital
    More analyst ratings